The V Foundation for Cancer Research, in partnership with the Goldberg Family Foundation and the Gray Foundation, has announced a $2.1 million commitment in support of promising new research on treatments for BRCA cancers.
In the years since mutations in BRCA genes were discovered to cause increased rates of breast and ovarian cancers, additional research has found that BRCA mutations can trigger a variety of cancers in men and women. When functioning properly, BRCA genes assist the body in preventing cancer. The grant will support research by a team at the University of California San Francisco's Center for BRCA Research focused on improving the effectiveness of PARP inhibitor (inhibitors of the enzyme poly ADP ribose polymerase) therapy, as well as options for combination therapies.
The foundations have been co-funding grants related to BRCA research since 2016 and together raised $7.5 million for cancer research in 2017. The V Foundation and Goldberg Family Foundation recently made a five-year commitment to raise $5 million in support of the BRCA Initiative.
"Our partnership with the V Foundation and the Gray Foundation has been a wild success and we are thrilled to continue it," said Evan Goldberg, member of the V Foundation board of directors and president, chair, and director of the BRCA Foundation. "Moving forward, the focus of our energies will be supporting the BRCA initiative at the V Foundation in order to eliminate the threat of BRCA cancers."